K-V Pharmaceutical Co . filed for Chapter 11 bankruptcy, a move it said was propelled by the U.S. Food and Drug Administration ‘s failure to enforce orphan drug exclusivity granted to K-V’s key premature-birth drug, Makena. Read the Dow Jones story here in Daily Bankruptcy Review.
[more]